New mechanism of disease discovered for Retinitis Pigmentosa
The team have found the cause of disease in the first ever family tree drawn up at Moorfields Eye Hospital over 35 years ago, which had remained unsolved until now.
Search results
The team have found the cause of disease in the first ever family tree drawn up at Moorfields Eye Hospital over 35 years ago, which had remained unsolved until now.
Biotechnology company ProQR has announced that two of its RNA therapy development programmes for inherited sight loss are being acquired by Laboratoires Théa, a company specialising in eye care products.
Cataracts occur fairly frequently and at a relatively early age within the Retina UK community of people with inherited retinal conditions. A question that comes up over and over again is whether or not to have cataract surgery.
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Retina UK invites expressions of interest to their first major innovation grant call, which will result in an award of up to £1million over five years as a strategic and targeted investment to result in transformative impact for therapy for inherited retinal dystrophy.
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
With Christmas parties upon us, come and join Bhavini as she shares her top tips for selecting the right make up, The best way to apply and blend, how to shop for makeup and picking the right colours.
Volunteers founded our charity in the 1970s and they continue to be at our heart.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.